These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9566702)

  • 21. Influence of pH on the binding of suramin to human serum albumin.
    Vansterkenburg EL; Wilting J; Janssen LH
    Biochem Pharmacol; 1989 Sep; 38(18):3029-35. PubMed ID: 2783157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
    Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
    J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action.
    Kalinowski L; Dobrucki LW; Szczepanska-Konkel M; Jankowski M; Martyniec L; Angielski S; Malinski T
    Circulation; 2003 Jun; 107(21):2747-52. PubMed ID: 12742996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of suramin against human prostate carcinoma DU145 xenografts in nude mice.
    Church D; Zhang Y; Rago R; Wilding G
    Cancer Chemother Pharmacol; 1999; 43(3):198-204. PubMed ID: 9923549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of the P2 receptors in rabbit pulmonary artery.
    Qasabian RA; Schyvens C; Owe-Young R; Killen JP; Macdonald PS; Conigrave AD; Williamson DJ
    Br J Pharmacol; 1997 Feb; 120(4):553-8. PubMed ID: 9051289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
    Takano S; Gately S; Neville ME; Herblin WF; Gross JL; Engelhard H; Perricone M; Eidsvoog K; Brem S
    Cancer Res; 1994 May; 54(10):2654-60. PubMed ID: 7513254
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of endogenous growth factors to support corneal endothelial migration after wounding in vitro.
    Schilling-Schön A; Pleyer U; Hartmann C; Rieck PW
    Exp Eye Res; 2000 Dec; 71(6):583-9. PubMed ID: 11095910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disruption of endothelial caveolae is associated with impairment of both NO- as well as EDHF in acetylcholine-induced relaxation depending on their relative contribution in different vascular beds.
    Xu Y; Henning RH; van der Want JJ; van Buiten A; van Gilst WH; Buikema H
    Life Sci; 2007 Apr; 80(18):1678-85. PubMed ID: 17335855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Procoagulant albumin increases vascular endothelial cell prostacyclin secretion.
    Gubler DB; Ahlstrom CR; Liu L; Zhou JF; Parker CJ; Rodgers GM
    Thromb Haemost; 1995 Dec; 74(6):1573-7. PubMed ID: 8772239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
    Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
    J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of suramin-albumin binding by electrospray mass spectrometry.
    Roboz J; Deng L; Ma L; Holland JF
    Rapid Commun Mass Spectrom; 1998; 12(19):1319-22. PubMed ID: 9773522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of continuous infusion suramin in metastatic breast cancer: impact on plasma levels of insulin-like growth factors (IGFs) and IGF-binding proteins.
    Lawrence JB; Conover CA; Haddad TC; Ingle JN; Reid JM; Ames MM; Suman VJ; Marks RS; Erlichman C; Hartmann LC
    Clin Cancer Res; 1997 Oct; 3(10):1713-20. PubMed ID: 9815555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
    Westermann AM; Dubbelman R; Baars JP; Moolenaar WH; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2000; 46(1):57-62. PubMed ID: 10912579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Location and characterization of the suramin binding sites of human serum albumin.
    Bos OJ; Vansterkenburg EL; Boon JP; Fischer MJ; Wilting J; Janssen LH
    Biochem Pharmacol; 1990 Oct; 40(7):1595-9. PubMed ID: 2222514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
    Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin A derivative.
    Finch PW; Yee LK; Chu MY; Chen TM; Lipsky MH; Maciag T; Friedman S; Epstein MH; Calabresi P
    Pharmacology; 1997 Dec; 55(6):269-78. PubMed ID: 9413855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suramin inhibits C6 glioma-induced angiogenesis in vitro.
    Coomber BL
    J Cell Biochem; 1995 Jun; 58(2):199-207. PubMed ID: 7545684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diadenosine polyphosphates in cultured vascular smooth-muscle cells and endothelium cells--their interaction with specific receptors and their degradation.
    Verspohl EJ; Johannwille B; Kaiserling-Buddemeier I; Schlüter H; Hagemann J
    J Pharm Pharmacol; 1999 Oct; 51(10):1175-81. PubMed ID: 10579689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dextran-shelled oxygen-loaded nanodroplets reestablish a normoxia-like pro-angiogenic phenotype and behavior in hypoxic human dermal microvascular endothelium.
    Basilico N; Magnetto C; D'Alessandro S; Panariti A; Rivolta I; Genova T; Khadjavi A; Gulino GR; Argenziano M; Soster M; Cavalli R; Giribaldi G; Guiot C; Prato M
    Toxicol Appl Pharmacol; 2015 Nov; 288(3):330-8. PubMed ID: 26276311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formyl peptide leukocyte chemoattractant uptake and release by cultured human umbilical vein endothelial cells.
    Rotrosen D; Malech HL; Gallin JI
    J Immunol; 1987 Nov; 139(9):3034-40. PubMed ID: 3668252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.